These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25349884)

  • 21. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention).
    Stefanini GG; Serruys PW; Silber S; Khattab AA; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; Di Mario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli AL; Gobbens P; Windecker S
    J Am Coll Cardiol; 2011 May; 57(22):2221-32. PubMed ID: 21616282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
    Silber S
    J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome].
    Gil RJ
    Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents.
    Mauri L; Massaro JM; Jiang S; Meredith I; Wijns W; Fajadet J; Kandzari DE; Leon MB; Cutlip DE; Thompson KP
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1240-9. PubMed ID: 21232717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
    Vardi M; Burke DA; Bangalore S; Pencina MJ; Mauri L; Kandzari DE; Leon MB; Cutlip DE
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1031-8. PubMed ID: 23737390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
    J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten-year outcomes from a randomised comparison of zotarolimus-eluting and sirolimus-eluting stents: the SORT OUT III study.
    Pareek M; Madsen M; Warnakula Olesen KK; Okkels Jensen L; Høj Christiansen E; Dalby Kristensen S; Flensted Lassen J; Thuesen L; Bøtker HE; Maeng M
    EuroIntervention; 2019 Dec; 15(11):e1022-e1024. PubMed ID: 31422923
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical outcomes of zotarolimus-eluting stents versus the first generation sirolimus-eluting stents and paclitaxel-eluting stents: a meta-analysis of randomized trials.
    Wei G; Fang Y; Yaqi R; Lin C; Ningfu W
    Int J Cardiol; 2012 May; 157(1):152-6. PubMed ID: 22464477
    [No Abstract]   [Full Text] [Related]  

  • 32. The process of bringing new drug-eluting stents to market will they see the light of day?
    Holmes DR; Patel M
    JACC Cardiovasc Interv; 2008 Oct; 1(5):533-4. PubMed ID: 19463355
    [No Abstract]   [Full Text] [Related]  

  • 33. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.
    Palmerini T; Kirtane AJ; Serruys PW; Smits PC; Kedhi E; Kereiakes D; Sangiorgi D; Bacchi Reggiani L; Kaiser C; Kim HS; De Waha A; Ribichini F; Stone GW
    Circ Cardiovasc Interv; 2012 Jun; 5(3):357-64. PubMed ID: 22668554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
    Leon MB; Mauri L; Popma JJ; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; McLaurin BT; Solomon SL; Douglas JS; Ball MW; Caputo RP; Jain A; Tolleson TR; Reen BM; Kirtane AJ; Fitzgerald PJ; Thompson K; Kandzari DE;
    J Am Coll Cardiol; 2010 Feb; 55(6):543-54. PubMed ID: 20152559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choice of drug-eluting stents.
    Med Lett Drugs Ther; 2012 Dec; 54(1406):102-3. PubMed ID: 23282791
    [No Abstract]   [Full Text] [Related]  

  • 37. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence.
    Byrne RA; Kastrati A
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):944-9. PubMed ID: 19021280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.
    Stone GW; Rizvi A; Sudhir K; Newman W; Applegate RJ; Cannon LA; Maddux JT; Cutlip DE; Simonton CA; Sood P; Kereiakes DJ;
    J Am Coll Cardiol; 2011 Jun; 58(1):19-25. PubMed ID: 21514084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.